Search Results

Avivagen Inc. has announced its unaudited financial results for the Second quarter of 2023.

Avivagen Inc. is pleased to announce that an existing customer has placed an order sized at 400% of its normal monthly order volume.

Avivagen Inc. announces several corporate updates, relating to the allowances of patents, a waiver of an interest payment on its senior secured debentures and the continuation of the strategic review process.

Avivagen Inc. announces that pursuant to its previously announced “Securities for Services” agreements with Top Meadow Consulting Services Inc. and Mr. Graham Burton, the Company has issued an aggregate of 507,345 common shares in the capital of the Company to Top Meadow Consulting Services Inc. and Mr. Graham Burton.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce two orders for OxC-beta™.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.

Avivagen Inc. announces that, pursuant to Policy 4.4 of the TSX Venture Exchange, it has entered into a “securities for services” agreement with each of Top Meadow Consulting Services Inc. and Mr. Graham Burton, pursuant to which the Company may elect to settle up to 15% of the fees or salary of such persons in common shares of the Company for the period from October 1, 2022 to February 28, 2023.

Avivagen Inc. has announced its unaudited financial results for the third quarter of 2022.

Avivagen Inc. today reported its audited financial results for the year ended October 31, 2022 and the implementation of a strategic plan to accelerate growth.

Avivagen Inc. announces that it has closed the second tranche of its previously announced non-brokered private placement financing through the issuance of common shares of the Company at a price of $0.20 per Share (for more information about the Offering and the first tranche thereunder, please see the Company’s news release dated October 21, 2022 for more details.